본문으로 건너뛰기
← 뒤로

Mitochondrial IκBα fuels cancer progression through metabolic rewiring, endothelial activation, and thrombotic spread.

1/5 보강
Cell death discovery 📖 저널 OA 94.8% 2022: 3/3 OA 2023: 1/1 OA 2024: 9/9 OA 2025: 61/61 OA 2026: 52/59 OA 2022~2026 2026
Retraction 확인
출처

Alessio M, Petiti J, Basile R, Poggio P, Acquarone D, Scalera A

📝 환자 설명용 한 줄

Mitochondria play a central role in metastatic spread and cancer progression, with the IκBα/NF-κB signaling axis acting as a key regulator of both processes.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Alessio M, Petiti J, et al. (2026). Mitochondrial IκBα fuels cancer progression through metabolic rewiring, endothelial activation, and thrombotic spread.. Cell death discovery. https://doi.org/10.1038/s41420-026-03022-0
MLA Alessio M, et al.. "Mitochondrial IκBα fuels cancer progression through metabolic rewiring, endothelial activation, and thrombotic spread.." Cell death discovery, 2026.
PMID 41888113 ↗

Abstract

Mitochondria play a central role in metastatic spread and cancer progression, with the IκBα/NF-κB signaling axis acting as a key regulator of both processes. We suggest that a stable fraction of IκBα localizes to mitochondria, where it escapes proteasomal degradation and acquires oncogenic functions independent of its canonical role in NF-κB inhibition. Using engineered A549 lung cancer cells with enforced mitochondrial localization of IκBα (IκBα-MTS), we show that the IκBα mitochondrial pool promotes increased cell proliferation, enhanced migration, and resistance to chemotherapy-induced apoptosis, along with a metabolic reprogramming characterized by elevated glycolysis and lactate secretion. These changes activated endothelial cells (ECs) and triggered cancer-associated thrombosis (CAT). This prothrombotic state, marked by elevated vWF a potent trigger for platelet adhesion and activation, contributed to an environment favorable for metastatic dissemination. Our findings reveal mitochondrial IκBα as a key mediator in mitochondrial stress, endothelial activation, and thrombo-inflammatory mechanisms that drive lung cancer progression.